Published By : 27 May 2016 | Published By : QYRESEARCH
The first of an infection that is resistant to all antibiotics in the market has been recently found in the U.S. Health officials in the country have expressed serious concern about the potential threat that the superbug may cause to other people if it starts spreading like other common infections.
Thomas Frieden, the director of the U.S. Centers for Disease Control and Prevention has said that people are at the risk of being in a post-antibiotic era. He was speaking about the case of urinary tract infection of a 49 year old women from Pennsylvania. Frieden was speaking at a Washington, D.C National Press Club luncheon. He said that the infection was not even cured by colistin, a class of antibiotics that is reserved for use in cases of the toughest bacterial infections.
The bacterial infection was first reported in a study that appeared in the Antimicrobial Agents and Chemotherapy, a journal published by the American Society for Microbiology. The report stated that the dreadful bacteria was itself first infected with a plasmid, which got passed along with a gene called mcr-1, conferring resistance to colistin.
This case represents the emergence of literally pan-antibiotics resistant bacterial classes and the need for greater, consistent, and much more wide ranging preventive measures to stay away from infections at the hands of such dreadful bugs.
The case may be the first such case of infection from an all-resistant bacteria, but the number of such cases is rising at an alarming rate across many countries in the world. Antibiotic resistance is to be blamed for thousands of deaths across the world in the current times and the number is expected to see a significant rise in the coming years.
Healthcare experts have been warning the healthcare industry since several decades that many superbugs could be on the rise across the globe but not many drugmakers attempted to develop medications against them. Now that the problem is actually affecting people and killing many every year, the need for new and highly effective antibiotics has arisen as one of the most pressing and urgent issues ahead of the healthcare industry.